生物标志物在新生儿脓毒症中的应用研究进展  

Advance of potential biomarkers in neonatal sepsis

作　　者：曹杨 刘瀚旻[1] Cao Yang;Liu Hanmin(Department of Pediatric Respiratory Immunology,Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University),Ministry of Education,West China Second University Hospital,Sichuan University,NHC Key Laboratory of Chronobiology(Sichuan University),Chengdu 610041,Sichuan Province,China)

机构地区：[1]四川大学华西第二医院小儿呼吸免疫科、出生缺陷与相关妇儿疾病教育部重点实验室,国家卫生健康委员会时间生物学重点实验室(四川大学),成都610041

出　　处：《中华妇幼临床医学杂志（电子版）》2021年第6期643-649,共7页Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)

基　　金：四川省科技厅重点研发项目(2019YFS0037)。

摘　　要：新生儿脓毒症(NS)是导致新生儿死亡的主要原因之一,其造成的新生儿死亡占比约为16%。根据NS发生时间,可被分为早发型NS(EONS)与晚发型NS(LONS)。由于对NS早期诊断迄今尚缺乏特异度高的生物标志物,导致对NS治疗延迟。为NS早诊断、早治疗,避免相关并发症的发生,研发可在NS早期诊断及预后判断中发挥优势的生物标志物具有至关重要的作用。目前,已经被广泛用于NS临床诊断及预后判断的生物标志物包括血清C反应蛋白(CRP)、降钙素原(PCT)、淀粉样蛋白A(SAA)等。笔者拟就NS分型和临床表现,NS患儿的诊断和治疗,生物标志物在NS诊疗和预后判断研究的最新现状进行阐述。Neonatal sepsis(NS),remains a major cause of mortality among neonates worldwide,accounting for approximately 16%neonatal mortality.NS is divided into early-onset neonatal sepsis(EONS)and late-onset neonatal sepsis(LONS).Nevertheless,the clinical therapy of NS is usually delayed due to lack of biomarkers with high specificity.Thus,it is crucial to investigate ideal biomarkers for earlier diagnosis and treatment of NS,and avoiding complications of neonates.Biomarkers have been widely used including C-reactive protein(CRP),procalcitonin(PCT)and serum amyloid A(SAA).We are aiming to summarize classifications and clinical characteristics,diagnosis and therapy,and advances of potential biomarkers in NS.

关 键 词：脓毒症 生物学标记 降钙素原 C反应蛋白质 细胞因子类 诊断 预后 婴儿 新生 

分 类 号：R72[医药卫生—儿科]